Statins in healthy over-70s: major AU trial changes the picture

There is a group of patients who sit in a clinical grey zone: people in their 70s, healthy, independent, no history of heart attack or stroke, no diabetes, no dementia — but with cardiovascular risk accumulating quietly over time. The question of whether to start a statin in this group has been genuinely contested. The standard approach has been cautious: primary prevention evidence in over-70s has been sparse, the benefits uncertain, the medication burden in this age group real.

New results from the Australian STAREE trial are shifting that picture.

STAREE — STAtins for Reducing Events in the Elderly — is a landmark Monash University-led randomised controlled trial of 9,971 Australians aged over 70 (mean age 74.5 years, 51.9% female). Participants had no prior cardiovascular disease, no diabetes, and no dementia at enrolment. Half received atorvastatin; half received placebo. They were followed for a median of 5.9 years. This is the largest primary prevention statin trial ever conducted in this age group.

The cardiovascular finding is substantial: a 30% reduction in major cardiovascular events in the atorvastatin group compared with placebo. That is a clinically meaningful result in a population that conventional wisdom has often regarded as beyond the window of primary prevention benefit.

---

Both sides of this

The result is not without its complication. The trial’s primary endpoint — disability-free survival, defined as living independently without significant cognitive or physical impairment — showed no significant difference between atorvastatin and placebo groups.

This is worth taking seriously. The trial was powered to detect a difference in disability-free survival, not just cardiovascular events. Participants in the statin arm had 30% fewer major cardiovascular events, but equivalent rates of living independently at the end of the study period. The two findings are not contradictory — heart disease is one contributor to disability and death among many in this age group — but they do mean the story is not simply “statins improve outcomes in over-70s.”

The 30% cardiovascular reduction is a secondary endpoint. In clinical trial hierarchy, a secondary endpoint that is positive while the primary endpoint is neutral requires care in interpretation. At the same time, a 30% reduction in heart attacks and strokes is not a number that can be dismissed as clinically unimportant in any age group. This is the interpretive tension at the centre of the findings.

A smaller recent study had suggested that older patients could safely de-prescribe statins without harm. The STAREE results directly contradict that suggestion for people who have not previously had a cardiovascular event. These are healthy over-70s who were not on statins; the question of stopping a statin in someone with established disease remains distinct.

Clinical commentators covering the findings expect updated guidelines. The Therapeutic Guidelines on cardiovascular risk management — the reference Australian GPs use — do not currently support broad statin initiation for primary prevention in over-70s without additional risk factors. That guidance is likely to be revisited.

---

What this means this week

For now, the evidence warrants a conversation — not a prescription.

If you are in your 70s without established cardiovascular disease, this is a study worth knowing about and worth raising with your GP. It does not mean a statin is right for you; it means the question is now better supported by evidence than it has been. The decision involves your individual lipid profile, blood pressure, family history, kidney function, current medications, and preferences about adding a long-term daily tablet.

No increase in serious adverse events was observed in the STAREE trial, which is reassuring on the safety question that often concerns both patients and clinicians in this age group. The statin used — atorvastatin — is a well-established agent with decades of post-market safety data.

For GPs: the clinical threshold for initiating a primary prevention statin conversation in an otherwise healthy 75-year-old has shifted. The patient who previously sat comfortably below the initiation threshold may now be in a zone worth active discussion. That conversation is not “here is your prescription” — it is “here is what the evidence now shows, here is how it applies to you, here is what you might gain and what else we need to consider.”

The evidence for statins in over-70s primary prevention was genuinely limited before STAREE. It no longer is.

---

Verdict: yes — the STAREE findings change the primary prevention conversation for patients over 70 and are likely to drive guideline updates.

The grey zone is smaller than it was. The question now is making sure the evidence reaches the consulting rooms where it matters.

---

Sources cited

1. Major Aussie study finds statins cut major CV events by 30% in healthy over-70s — Australian Doctor, September 2026